Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ginkgo, under a grant from the Bill & Melinda Gates Foundation, will work to develop a live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria directly in the body Ginkgo will apply its cell engineering expertise towards creating a fundamentally new cell-based therapeutic delivery modality which could change the future of biologics delivery in medicine BOSTON , Dec. 13, 2023 /PRNewswire/ -- – Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, has received a grant from the Bill & Melinda Gates Foundation to develop a novel cell-based technology for improving protein therapeutics delivery for patients in low- and middle-income countries (LMICs). Protein therapeutics have transformed the standard of care for many diseases — the best known example being insulin for diabetes — and have helped to extend lives across the world, thanks to revolutionizing treatments of diseases such as anemia, cancers, and certain genetic disorders.

Ginkgo Bioworks Receives Grant to Develop Innovative Live Cell Delivery Platform of Antibody Therapeutics for Treating HIV and Malaria

Etsy

Moderna

Stocks won't automatically become more expensive when we shift into a new year. But those that have struggled this year and have strong long-term outlooks could rebound at any point.

3 Dirt-Cheap Stocks to Buy Hand Over Fist Before the End of the Year

Arbor, a biotechnology company discovering and developing the next generation of genetic medicines, will leverage Ginkgo's R&D services to further optimize Arbor's novel precision editors Arbor's portfolio of novel gene editors has significant therapeutic potential because of their unique protospacer adjacent motifs, varied cut types, smaller editing technology, and high specificity Ginkgo's high-throughput Mammalian Foundry enables companies like Arbor to optimize novel gene editors with improved functional characteristics by screening in mammalian cells CAMBRIDGE, Mass. and BOSTON , Dec. 12, 2023 /PRNewswire/ -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced a collaboration with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, to leverage Ginkgo's comprehensive Codebase and automated Foundry to jointly optimize Arbor's novel precision editors.

Arbor Biotechnologies Announces Collaboration with Ginkgo Bioworks to Advance the Discovery and Development of Precision Gene Editors

SÃO PAULO and BOSTON , Dec. 8, 2023 /PRNewswire/ -- Agrivalle, a leading Brazilian agricultural biologicals company, today announced a new partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. Together, the companies will collaborate on building cutting edge technologies to advance Agrivalle's biological products, including next-gen fertilizers and biocontrol agents.

Agrivalle and Ginkgo Bioworks Enter Multiyear Strategic Partnership to Accelerate Next-Gen Ag Biological Products

Synplogen, a synthetic biology startup spun out of Kobe University's Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy Biofoundry™ services, has entered into a non-binding Memorandum of Understanding ("MOU") with Ginkgo Bioworks with the intent to advance global DNA manufacturing and gene therapy platform services within the Japanese market Synplogen intends to support and introduce Ginkgo's gene therapy services within the Japanese biotechnology and pharmaceutical ecosystem KOBE, Japan and BOSTON , Dec. 6, 2023 /PRNewswire/ -- Synplogen Co., a synthetic biology startup spun out of Kobe University's Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy Biofoundry services, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a non-binding Memorandum of Understanding ("MOU"). Together, Synplogen and Ginkgo intend to accelerate the global development of DNA manufacturing and gene therapy platform services in Japan.

Synplogen and Ginkgo Bioworks Announce Plans to Accelerate Global DNA Manufacturing and Gene Therapy Platform Services in Japan

CRISPR Therapeutics

These companies are just getting started along the path of revenue growth. Their technologies -- gene editing and organism engineering -- help them stand out from the crowd.

Looking for Growth? 2 Top Stocks to Buy Hand Over Fist

Arcos Dorados Hlds

AST SpaceMobile

BuildABear

Hudson Technologies

Redwood Trust

Vir Biotechnology

Small-cap stocks to buy offer a window into the future of the global economy, encapsulating companies with market capitalizations upwards of $250 million and $2.5 billion. These are the potential giants of tomorrow, starting as small-caps and gradually ascending to large or even mega-cap status through consistent earnings expansion.

7 Small-Cap Stocks to Buy BEFORE the Year-End Rally

Amyris Inc

Codexis

Synthetic biology refers to using engineered organisms to produce products for multiple industries. Specifically, the pharmaceutical, biotechnology, and agriculture sectors are set to benefit most from synthetic biology.

3 Synthetic Biology Stocks Likely to Mint New Millionaires

Vivici has formed a partnership with Ginkgo to advance production of a sustainable and nutritious dairy protein, made via precision fermentation. Ginkgo will use its Protein Production Services and  generative AI platform to deliver best-in-class candidate strains to Vivici.

Vivici Selects Ginkgo Bioworks to Extend Their Range of Novel Dairy Proteins

The cell programming upstart is partnering with behemoths like Pfizer and Alphabet. The business remains unproven, incurring heavy losses over the past four quarters.

Where Will Ginkgo Bioworks Be in 5 Years?

Aehr Test Systems

Enovix Corporation

Hims & Hers Health

Rocket Lab USA

Recursion Pharmaceuticals

Finding a great small-cap stock to buy isn't always easy. We know that, over the long run, small-cap stocks as a whole outperform large-cap cousins.

2024's Hidden Gems: 7 Small-Caps Set for Explosive Growth

Ginkgo Bioworks' Q3 results were relatively poor due to the difficult macro environment and the winding down of its COVID testing business. While Ginkgo's Cell Engineering business has enormous potential, data indicates that this business is still nascent. Investors expecting significant downstream value will need to be patient. Progress amongst pharmaceutical and biotech customers is an important development but most of these programs are yet to be completed.

Ginkgo Bioworks: A Long Way To Go

Ginkgo Bioworks is successfully scaling its customer base. It's also making some progress towards profitability.

3 Key Trends to Consider in Ginkgo Bioworks' Q3 Earnings Report

Aurora Cannabis

Amicus Therapeutics

Lyft

Mullen Automotive

Peloton

Virgin Galactic

WeWork's (OTCMKTS: WEWKQ ) spectacular failure and recent bankruptcy filing should serve as a cautionary tale for many other troubled stocks. It should also serve to renew efforts to reassess one's portfolio and drop stocks that are bound to act as detractors overall.

7 Stocks Most Likely to Follow in WeWork's Woeful Footsteps

Ginkgo Bioworks (NYSE: DNA) stock price is nearing the lowest level on record as its revenue and profitability metrics remain under pressure. The shares have also plunged after signs emerged that its insiders were selling the stock.

Ginkgo Bioworks (DNA): Insiders are selling Cathie Wood-backed stock

ExScientia Ltd

Schrodinger 

Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks. Fundamentally, the reasoning centers on relative insulation.

3 Cutting-Edge Biotech Stocks for the Bold Investor

Intuitive Surgical

Cathie Wood loves to pick up shares of innovators while they're down -- because she counts on gains over time. Wood's flagship exchange-traded fund is outperforming the S&P 500 so far this year.

3 Cathie Wood Bargain Buys That Should Be on Your List Too

Ginkgo Bioworks Holdings Inc. (NYSE:DNA ) Q3 2023 Results Conference Call November 8, 2023 5:30 PM ET Company Participants Megan LeDuc - Manager of Investor Relations Jason Kelly - Founder, CEO & Director Mark Dmytruk - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Poon Mah - TD Cowen Derik Bruin - BofA Securities Michael Freeman - Raymond James E.V. Koslosky - Goldman Sachs Megan LeDuc Good evening.

Ginkgo Bioworks Holdings Inc. (DNA) Q3 2023 Earnings Call Transcript

No investor likes a big earnings miss. While the biotech beat on the top line for its third quarter, that bottom-line whiff was glaring.

Why Ginkgo Bioworks Stock Was Plummeting on Thursday

Alkermes

Amphastar Pharma

DaVita

Jazz Pharmaceuticals

OraSure Technologies

United Therapeutics

If you're a fan of the hit TV show Shark Tank, you've probably come across the intriguing term “unicorn” companies. Indeed, these fantastical entities are not only confined to the realm of imagination.

7 Healthcare Stocks That Are Poised to Become the Next Unicorns

Foremost aims to commercialize a technology that can convert dairy manufacturing co-products into environmentally friendly, value-added materials The partners aim to reduce the dairy industry's carbon footprint while simultaneously lowering manufacturing costs and creating a significant new revenue stream for the hundreds of Midwest dairy farmer members comprising the Foremost Farms cooperative  Foremost Farms will leverage Ginkgo's bioproduction services and market-leading metabolic engineering and analytical capabilities to advance this novel technology MIDDLETON, Wis. and BOSTON , Nov. 9, 2023 /PRNewswire/ -- Foremost Farms USA, a world-class producer of cheese, butter, and dairy ingredients supplied to national and international markets, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to use advances in biotechnology to enable domestic, sustainable biomanufacturing of materials from dairy co-products to benefit the environment, family farms and the dairy industry as a whole.

Foremost Farms Selects Ginkgo Bioworks to Develop Technology for Upcycling Dairy Co-products

Ginkgo added 21 new Cell Programs to the Foundry platform in Q3 2023 Entered into strategic cloud and AI partnership with Google Cloud; first milestone recently achieved Signed new multi-target RNA drug discovery collaboration with Pfizer in which Ginkgo is eligible to receive research fees and development and commercial milestone payments of up to $331 million Ginkgo ended Q3 2023 with over $1.0 billion in cash and cash equivalents, maintaining a multi-year runway as Ginkgo continues to drive towards profitability BOSTON , Nov. 8, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2023. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports Third Quarter 2023 Financial Results

XWELL Inc

The program can be an effective early warning system for public health and national security officials, leveraging voluntary nasal and wastewater sampling from international travelers at major U.S. airports BOSTON , Nov. 6, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and XWELL, Inc. (Nasdaq: XWEL) today announced they are expanding their work with the U.S. Centers for Disease Control and Prevention's (CDC's) Traveler-based Genomic Surveillance program (TGS) to test for more than 30 additional priority pathogens, in addition to SARS-CoV-2. TGS is a flexible, multimodal platform that consists of three complementary approaches of sample collection from arriving international travelers at U.S. airports, including voluntary nasal swabbing, aircraft wastewater, and airport wastewater sampling to enhance early detection of new SARS-CoV-2 variants and other pathogens, and fills gaps in global surveillance.

Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens

Presentation and Q&A session scheduled for post-market on Wednesday, November 8, 2023 BOSTON , Nov. 1, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2023, on Wednesday, November 8, 2023, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.

Ginkgo Bioworks Announces Date of Third Quarter 2023 Results Presentation

Ginkgo Bioworks is analyzed based on Porter's Five Forces framework for competitive dynamics. The threat of competition in Ginkgo's R&D discovery business is low due to its unique offerings and limited number of competitors. Ginkgo has been able to convert large pharmaceutical companies onto its Foundry Platform which suggests that the threat of substitution is becoming lower and lower.

News for Ginkgo Bioworks Holdings Stock (DNA)